Results 211 to 220 of about 100,944 (279)

The Impact of Surfactant Protein‐D Gene Polymorphism on COVID‐19 Clinical Outcomes

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Background COVID‐19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), presents a broad spectrum of clinical manifestations, ranging from asymptomatic cases to severe, life‐threatening respiratory complications. Pulmonary surfactant‐associated protein D (SP‐D) is a critical component of pulmonary immune defense.
Nadia Nasirzadeh Kolsari, Azarakhsh Azaran, Roya Pirmoradi, Maryam Moradi, Roohangiz Nashibi, Shahram Jalilian   +5 more
wiley   +1 more source

Severe Cytokine Release Syndrome After CAR T Cell Therapy in a Pediatric Patient With Relapsed ALL. [PDF]

Case Rep Oncol Med
Alotaibi A, Alajmi N, Alnuhait M.
europepmc   +1 more source

Impact of Early COVID‐19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Hou‐Ting Kuo, Alan Y. Hsu, De‐Yi Liu, Bing‐Qi Wu, James Cheng‐Chung Wei, Ning‐Yi Hsia, Yi‐Ching Shao, Chun‐Ting Lai, Chun‐Chi Chiang, Chun‐Ju Lin, Huan‐Sheng Chen, Yu‐Hsun Wang, Hsin Tseng, Ho‐Che Hsu, Yi‐Yu Tsai   +14 more
wiley   +1 more source

Case Report: Anti-TNF-α therapy-associated destructive thyroiditis and unmasking of latent amyloid A amyloidosis in rheumatoid arthritis. [PDF]

Front Immunol
Kumagai K, Okumura N, Mimura T, Yayama T, Kubo M, Imai S.   +5 more
europepmc   +1 more source

A certolizumab pegol kezelés rheumatoid arthritisben, irodalmi áttekintés és egészség-gazdaságtani elemzés = Certolizumab pegol in patients with rheumatoid arthritis: systematic review and health economic evaluation [PDF]

, 2009
Brodszky, Valentin, Gulácsi, László, Péntek, Márta, Érsek, Katalin   +3 more
core  

CAR‐T Cells: Current Status, Challenges, and Future Prospects

MedComm, Volume 7, Issue 5, May 2026.
This graphical abstract outlines the current status, challenges, and future prospects of CAR‐T cells. The biological basis of CAR‐T cell therapy is the elegant redirection of adaptive immunity. Its initial successes have exposed a landscape of multifaceted challenges.
Aya Sedky Adly, Guillaume Cartron, Afnan Sedky Adly, Jean‐Christophe Egea, Pierre‐Yves Collart Dutilleul, Mahmoud Sedky Adly, Martin Villalba   +6 more
wiley   +1 more source

Interleukin-6 Inhibitor-Induced Leukocytoclastic Vasculitis: A Case Report With a Literature Review. [PDF]

Case Reports Immunol
Aloyan T, Salimova D, Mohamed E, Wazir H.   +3 more
europepmc   +1 more source

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

Cytokine release syndrome after allogeneic hematopoietic stem cell transplantation using posttransplant cyclophosphamide: current understanding and management. [PDF]

Front Immunol
Wang J, Arora K, de Lima M.
europepmc   +1 more source